Press Release
Astellas Announces Status of Acquisition of Own Shares(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)
Tokyo, November 1, 2016 - Astellas Pharma Inc. (Tokyo:4503, President and CEO: Yoshihiko Hatanaka, hereinafter called "the Company") announced status of the acquisition of its own shares as stated below. The acquisition was implemented pursuant to Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.
Particulars
Class of shares acquired: Common stock of the Company
Total number of shares acquired: 1,128,500 shares
Aggregate amount of acquisition cost: 1,760,341,300 yen
Date of acquisition: October 31, 2016
Method of acquisition: Purchased on the Tokyo Stock Exchange (Reference)
Details of the resolution at the meeting of the Board of Directors (announced on October 28, 2016)
Class of shares to be acquired: Common stock of the Company
Total number of shares to be acquired: Up to 30 million shares
(The percentage compared to the total number of shares outstanding: 1.41%)
Aggregate amount of acquisition cost: Up to 50 billion yen
Period of acquisition: From October 31, 2016 to December 22, 2016
Accumulated Company's own shares acquired through October 31, 2016, pursuant to the above board resolution
Total number of shares acquired: 1,128,500 shares
Aggregate amount of acquisition cost: 1,760,341,300 yen
######
1
About AstellasAstellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.
Contacts for inquiries or additional information:Astellas Pharma Inc. Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473
Astellas Pharma Inc. published this content on 01 November 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 01 November 2016 02:02:04 UTC.
Original documenthttps://www.astellas.com/en/corporate/news/pdf/161101_Eg.pdf
Public permalinkhttp://www.publicnow.com/view/48D55C2BE2E4A2C1615E78ED565B4C6377D74F83